Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Background The direct oral anticoagulants (DOACs) reduce the risk of stroke in moderate to
high-risk patients with non-valvular atrial fibrillation (AF). Yet, concerns remain regarding its …

Introduction Medications cannot exert their effect if not taken as prescribed by patients. Our
objective was to summarise the observational evidence on adherence to oral anticoagulants …

Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke
prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence …

Background and Purpose Data on oral anticoagulant (OAC) uptake and pattern of use are
limited. Real‐life data in patients with atrial fibrillation (AF) are important for understanding …

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for
prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF). Increased use of …

Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Background This study assessed changes in anticoagulation therapy over time in patients
with atrial fibrillation (AF). Methods Analyses were performed on a claims-based dataset of 4 …

Aims To investigate the association between adherence to non-vitamin K antagonist oral
anticoagulant (NOAC) and clinical outcomes and to determine the optimal cut-off level of …